×

Alan W. Milinazzo Elected to CASMED Board of Directors

BRANFORD, Conn., June 30, 2015 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (NASDAQ:CASM) (CASMED), a leader in providing medical products for the non-invasive patient monitoring of tissue oxygenation, announces the election of Alan W. Milinazzo to the Company's Board of Directors. Mr. Milinazzo's election became effective as of June 23, 2015, following the Company's annual meeting of stockholders, and increased the size of CASMED's Board to seven (7) Directors. Mr. Milinazzo will serve on the Compensation Committee.

Mr. Milinazzo is President and CEO of InspireMD, Inc., a publicly-traded, interventional device company focused on developing novel embolic protection products, where he has served since 2013. Prior to InspireMD he was CEO of Orthofix International, N.V., a global orthopedic company. Mr. Milinazzo previously held executive positions at Medtronic Inc., Aspect Medical Systems, Inc. and Boston Scientific Corporation.

Mr. Milinazzo is a Director of InspireMD, Inc. and serves on the Boards of the Musculoskeletal Transplant Foundation and Flexion Therapeutics. He formerly served on the Boards of Orthofix International, N.V., Medpace, and HET Systems. He holds a Bachelor's Degree from Boston College.

"Alan's experience as a senior executive and board member provides CASMED with another key resource as we continue to develop a high-growth, profitable and global healthcare businesses. With more than 25 years of experience in the management and marketing of medical devices, along with expertise in the cardiovascular and patient monitoring fields, Alan brings valuable context and insights to commercial strategies and operational issues," said Thomas M. Patton, President and CEO of CASMED. "We welcome Alan to our Board."

About CASMED® – Monitoring What's Vital

CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT® Absolute Cerebral Oximeter provides a highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care. For more information regarding CASMED, visit the Company's website at www.casmed.com.

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company's Form 10-K for the year ended December 31, 2014, and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Company Contact
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
(203) 315-6303
ir@casmed.com

Investors
LHA
Jody Cain - jcain@lhai.com
Bruce Voss - bvoss@lhai.com
(310) 691-7100
@LHA_IR_PR

Source:CAS Medical Systems, Inc.